ISPOR Asia Consortium Advisory Committee


ISPOR Asia Consortium Advisory Committee is a group of individuals who have demonstrated a continuing interest in advancing the science of pharmacoeconomics and outcomes research in Asia, as well as have encouraged the use of this science by healthcare decision-makers in this region. Members of the Advisory Committee may or may not be a resident of a country in Asia or may or may not be an ISPOR member.  

The Advisory Committee advises the Executive Committee on new initiatives, health science or health policy issues, and other activities of the Consortium.

ISPOR ASIA Consortium Advisory Committee Membership

Membership on the ISPOR Asia Consortium Advisory Committee is determined by the Executive Committee. The term for an Advisory Committee member is 3 years and is renewable. Members who are inactive (i.e. do not participate in Consortium activities via email or teleconference over a 6 month period) will be asked to resign. Membership of the Advisory Committee is evaluated each year to assure that all work environments, as well as country perspectives are represented on the Committee (academia, research organizations, health decision-makers, and industry).

Advisory Committee Officers

The ISPOR Asia Consortium Advisory Committee is led by the Advisory Committee Chair. 

Chair/Chair-elect

The Chair is selected initially by the ISPOR Asia Consortium Executive Committee, and then elected by the ISPOR Advisory Committee members. The term of the Chair is 2 years. All interested Advisory Committee members are eligible to be candidates. All Advisory Committee members are eligible to vote. The candidate with the majority votes is the new Chair-elect.
The Chair conducts the election.

ISPOR Asia Consortium Advisory Committee

CHAIR (2009-2011)
 
Mingliang Zhang PhD, Senior Director, Health Economics Immunology, Worldwide Health Economics and Pricing, Johnson and Johnson Pharmaceutical Services, PA, USA
E-mail: MZhang5@its.jnj.com

CHAIR-ELECT (2009-2011) AND CHAIR (2011-2013)
Jennifer Sung PharmD, MS, Executive Director, Global Health Economics & Outcomes Research, Novartis, Shanghai, China
E-mail: jennifer.sung@novartis.com

ISPOR ASIA CONSORTIUM ADVISORY COMMITTEE MEMBERS:

ASIA
Government, Academia and Institutes:

  • Jeonghoon Ahn PhD, MA, Director, Economic Evaluations, National Evidence-based Healthcare Collaborating Agency (NECA), Seoul, Korea
  • Carol Cheng, PhD, Operating Officer, International Research-Based Pharmaceutical Manufactures Association (IRPMA), Taipei, Taiwan
  • Hye-Young Kang, R.Ph, PhD, Associate professor, Graduate School of Public Health,  Executive committee, Institute of Health Services Research, Yonsei University, Seoul, Korea

Consulting:

  • Bruce Crawford MA, MPH, General Manager, Asia, Mapi Values, Tokyo, Japan

Industry:

  • William Bishop, Director, Government Affairs, Nippon Becton Dickinson Company, Ltd., Tokyo, Japan
  • Kevin C. Chen, Vice President, Asia, International Research-based Pharmaceutical Manufacturing Association, Taipei, Taiwan
  • Seong-Choon Choe MD, PhD, Director, Medical Department, Roles and Responsibilities, sanofi-aventis Korea, Seoul, Korea
  • Izhar M. Hussain, Director, Business Excellence and Development, Abbott Laboratories (Pakistan) Ltd, Pakistan
  • Hong Li PhD, MPH, Group Director, Outcomes Research, and Vice President, Market Access, China, Bristol-Myers Squibb Company Asia-Pacific, Singapore
  • Lillian Yu-Jen Wang, MS, Market Access Manager, Novartis (Taiwan) Co., Ltd., Taipei, Taiwan

NON-ASIA

Government, Academia and Institutes:

  • Rajesh Balkrishnan, PhD, Merrell Dow Professor, Ohio State University College of Pharmacy and School of Public Health, Columbus, OH, USA
  • John Bian PhD, Health Services Research, American Cancer Society, Atlanta, GA, USA
  • Hua Chen PhD, Department of Clinical and Administration, College of Pharmacy, University of Houston, Texas Medical Center, Houston, TX, USA
  • Jalpa A. Doshi PhD, Research Assistant Professor, General Internal Medicine, University of Pennsylvania, Philadelphia, PA, USA
  • Christian Gericke MD MPH MSc FACP, Professor and Chair in Public Health Policy, The University of Adelaide Adelaide, Australia
  • Jeff J. Guo B. Pharm., PhD (founder), Associate Professor of Pharmacoeconomics & Pharmacoepidemiology, Division of Pharmacy Practice & Administrative Sciences, James L. Winkle College of Pharmacy (& Faculty Research Fellow, Institute for the Study of Health), University of Cincinnati Medical Center, Cincinnati, OH, USA
  • Dong-Churl Suh MBA, Ph.D, Associate Professor, Department of Pharmacy Practice and Administration, College of Pharmacy--Busch Campus Rutgers, the State University of New Jersey, Piscataway, NJ USA
  • Peter K. Wong, PhD, MBA, MS, RPh, Vice President, Quality and Clinical Effectiveness, Mercy Health Partners, Southwest Ohio Cincinnati, Ohio, USA
  • Hong Xiao PhD, Associate Professor, Division of Economic, Social and Administrative Pharmacy, College of Pharmacy and Pharmaceutical Sciences Florida A&M University, Tallahassee, FL, US

Consulting:

  • Brian P. Harrigan, Chief Operating Officer, Oxford Outcomes, Vancouver, B.C. V6B 1P1, Canada

Industry:

  • Jim P. Doherty MSHA, PhD,Therapeutic Area Lead, Global health Outcomes, GlaxoSmithKline, Research Triangle Park, NC, USA
  • Sandeep Duttagupta, PhD, Senior Director, Market Access Leader, Emerging Markets Business Unit. Pfizer Inc., New York, NY, USA
  • Amy Guo PhD, Associate Director, Health Economics & Research Outcomes, Medical Affairs, Berlex, Montville, NJ, USA
  • Xing-Yue Huang MS,PhD, Health Economics Sr. Manager, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, CA, USA
  • Sheldon Kong PhD, Head, Global Outcomes Research, Merck & Company, Inc., Whitehouse Station, NJ, USA
  • Linda C. Koo, PhD, Director, Discovery Medicine and Epidemiology AstraZeneca, Wilmington DE, USA
  • Roger G. Luo PhD, MA, MS, Associate Director, Health Economics & Outcomes Research, AstraZeneca, Wilmington, DE, USA
  • Siew Hwa Ong, MSc, Health Economist, New Product Pricing and Health Economics, Novartis Pharma AG, Basel, Switzerland
  • Manny Papadimitropoulos PhD, Director, Health Outcomes Research, Intercontinental Region and Japan, Eli Lilly and Company, Toronto, ON, Canada
  • Eugene G Salole PhD, Senior Manager, Outcomes Research & Market Access (Asia), Pfizer Australia, West Ryde, Australia
  • Jennifer Sung PharmD, MS, Executive Director, Global Health Economics & Outcomes Research, Novartis, Shanghai, China
  • Fang Wang, PhD, Director, HEOR, Cephalon, PA, USA
  • Jasmanda Hsiao-Hui Wu PhD, MPH, Associate Director, Outcomes Research, Ortho-McNeil Janssen Scientific Affairs, L.L.C., Johnson & Johnson, Titusville, NJ.  USA
  • Mingliang Zhang PhD, Senior Director, Health Economics Immunology, Worldwide Health Economics and Pricing, Johnson and Johnson Pharmaceutical Services, PA, USA
  • Zhongyun Zhao PhD, Director, Global Health Economics, Amgen Inc., Thousand Oaks, CA, USA

Advisory Committee Special Representatives

Special Representatives to the Asia Consortium Advisory Committee are for the interested people that their organizations have formal members on the Advisory Committee.

ISPOR Asia Consortium Advisory Committee Meetings

The Asia Consortium Executive Committee and Advisory Committee meet at least three times a year via teleconference and one face-to-face meeting at the ISPOR Annual Meeting, European Congress, or Asia-Pacific Conference... The Executive Committee and Advisory committee meet via teleconference separately or together, determined by the Chairs.

Back to Asia Consortium main page

 

Contact ISPOR @ info@ispor.org  |  View Legal Disclaimer
©2010 International Society for Pharmacoeconomics and Outcomes Research. All rights reserved under International and Pan-American Copyright Conventions. 
Website design by Eagle Systems USA, Inc.